San Francisco: The US Worldwide Commerce Fee (ITC) has denied Apple’s bid to delay an import and gross sales ban on the Watch Sequence 9 and Watch Extremely 2 amid a patent dispute.
In a submitting late on Wednesday, the US ITC mentioned it has “decided to disclaim the respondent’s movement to remain remedial orders pending enchantment and/or in gentle of potential authorities shutdown”.
The long-running patent dispute between Apple and medical expertise firm Masimo is across the Watch’s blood oxygen sensor (SpO2 sensor) expertise.
An October ruling from the ITC mentioned the tech big’s SpO2 sensors infringed on patents from Masimo.
The final day to buy the Watch Sequence 9 and Extremely 2 from Apple shops is December 24, whereas the import ban formally goes into impact on December 26.
Apple is reportedly engaged on software program modifications on how the Watch measures and stories oxygen saturation.
The ban additionally solely impacts gross sales of the Sequence 9 and Extremely 2 inside the US and the watches will nonetheless be out there on the market overseas.
Masimo is thought for its pulse oximeter. The corporate had filed two separate circumstances, claiming that Apple infringed on its pulse oximetry expertise.
An Apple spokesperson mentioned earlier that it “strongly disagrees” with the order and is “pursuing a spread of authorized and technical choices to make sure that Apple Watch is out there to clients.”
The ITC import ban ruling is presently present process a presidential evaluation interval, and US President Joe Biden may have the chance to veto the ban.
